Greener, more sustainable platforms for high-value recombinant protein production

Acronym

greenerRPP

Description of the granted funding

The greenerRPP project aims to markedly enhance the EU’s capacity for the production of secreted high-quality recombinant proteins, especially industrial enzymes and therapeutic proteins (biotherapeutics). The combined markets are in excess of $330 billion p.a., and the products are of massive significance for healthcare and a sustainable bio-based economy. greenerRPP will address urgent problems in these industries, such as difficult-to-express proteins and the rapidly-emerging issue of 'sustainability' in the European biotechnology industry. It will deliver improvements in yield and process design that increase the industry's effectiveness while simultaneously reducing high current levels of waste. It will deliver industrial enzymes that reduce energy and raw material costs in countless industrial and domestic settings. To achieve this, we will develop powerful new microbial and mammalian cell platforms that produce recombinant proteins in unusually high quantities and in unparalleled quality, and bring to market a suite of super-producing platforms. A comprehensive training programme will equip greenerRPP ESRs with the interdisciplinary and intersectoral skills required to be future leaders in these industries, while emphasising sustainability and gender-diversity dimension principles at every level. Finally, the programme addresses the stark global inequality in this biotechnology sector: recombinant protein production is largely carried out in (or outsourced by) high-income countries, placing low/middle income countries at a massive disadvantage. greenerRPP includes a series of South East Asian Institutions as Associated Partners, to develop a global network with a knowledge exchange-secondment programme that boosts these countries' own manufacturing programmes. greenerRPP ESRs will thus enhance a European industrial sector that has never been more important to society, while making it 'greener' and reaching out to lower income countries.
Show more

Starting year

2022

End year

2026

Granted funding

572 976 €
Participant
EV BIOTECH BV (NL)
Participant
UNIVERSITI MALAYSIA SABAH (MY)
Participant
UNIVERSITATSMEDIZIN GREIFSWALD KORPERSCHAFT DES OFFENTLICHEN RECHTS (DE)
260 539.2 €
Participant
BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT)
270 331.2 €
Participant
AB Enzymes GmbH (DE)
Participant
MAHIDOL UNIVERSITY (TH)
Participant
National Institute for Bioprocessing Research and Training Ltd (IE)
286 488 €
Participant
DSM FOOD SPECIALTIES BV (NL)
137 185.2 €
Participant
NATIONAL INSTITUTE OF VETERINARY RESEARCH (VN)
Participant
UNIVERSITY OF KENT (UK)
Participant
UNIVERSITAET GREIFSWALD (DE)
260 539.2 €
Participant
KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI (TH)
Participant
ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
685 926 €
Coordinator
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH (CH)
Participant

Amount granted

2 473 985 €

Funder

European Union

Funding instrument

HORIZON TMA MSCA Doctoral Networks

Framework programme

Horizon Europe (HORIZON)

Call

Programme part
Marie Skłodowska-Curie Actions (MSCA) (11677)
Topic
MSCA Doctoral Networks 2021 (HORIZON-MSCA-2021-DN-01-01)
Call ID
HORIZON-MSCA-2021-DN-01

Other information

Funding decision number

101073056

Identified topics

biomass, bioeconomy